Logo image of TALS

TALARIS THERAPEUTICS INC (TALS) Stock Fundamental Analysis

NASDAQ:TALS - Nasdaq - US87410C1045 - Common Stock - Currency: USD

2.72  -0.02 (-0.73%)

After market: 2.75 +0.03 (+1.1%)

Fundamental Rating

3

Overall TALS gets a fundamental rating of 3 out of 10. We evaluated TALS against 566 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for TALS as it has an excellent financial health rating, but there are worries on the profitability. TALS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TALS has reported negative net income.
In the past year TALS has reported a negative cash flow from operations.
TALS Yearly Net Income VS EBIT VS OCF VS FCFTALS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

TALS has a Return On Assets (-46.99%) which is in line with its industry peers.
TALS's Return On Equity of -50.38% is fine compared to the rest of the industry. TALS outperforms 64.29% of its industry peers.
Industry RankSector Rank
ROA -46.99%
ROE -50.38%
ROIC N/A
ROA(3y)-24.01%
ROA(5y)N/A
ROE(3y)-25.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TALS Yearly ROA, ROE, ROICTALS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -10 -20 -30 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TALS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TALS Yearly Profit, Operating, Gross MarginsTALS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022

More info and screens

8

2. Health

2.1 Basic Checks

TALS has more shares outstanding than it did 1 year ago.
TALS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TALS Yearly Shares OutstandingTALS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M 40M
TALS Yearly Total Debt VS Total AssetsTALS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 4.50 indicates that TALS is not in any danger for bankruptcy at the moment.
The Altman-Z score of TALS (4.50) is better than 81.89% of its industry peers.
TALS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.5
ROIC/WACCN/A
WACCN/A
TALS Yearly LT Debt VS Equity VS FCFTALS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 100M 200M

2.3 Liquidity

A Current Ratio of 15.41 indicates that TALS has no problem at all paying its short term obligations.
The Current ratio of TALS (15.41) is better than 87.38% of its industry peers.
A Quick Ratio of 15.41 indicates that TALS has no problem at all paying its short term obligations.
TALS's Quick ratio of 15.41 is amongst the best of the industry. TALS outperforms 87.38% of its industry peers.
Industry RankSector Rank
Current Ratio 15.41
Quick Ratio 15.41
TALS Yearly Current Assets VS Current LiabilitesTALS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

TALS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.79%, which is quite impressive.
EPS 1Y (TTM)24.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TALS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.08% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.08%
EPS Next 2Y18.99%
EPS Next 3Y3.04%
EPS Next 5Y9.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TALS Yearly Revenue VS EstimatesTALS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 100M 200M 300M
TALS Yearly EPS VS EstimatesTALS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TALS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TALS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TALS Price Earnings VS Forward Price EarningsTALS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TALS Per share dataTALS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.99%
EPS Next 3Y3.04%

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 55.58%, TALS is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 52.36, TALS pays a better dividend. On top of this TALS pays more dividend than 99.83% of the companies listed in the same industry.
TALS's Dividend Yield is rather good when compared to the S&P500 average which is at 2.46.
Industry RankSector Rank
Dividend Yield 55.58%

5.2 History

TALS does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
TALS Yearly Dividends per shareTALS Yearly Dividends per shareYearly Dividends per share 2023 0.5 1 1.5

5.3 Sustainability

DPN/A
EPS Next 2Y18.99%
EPS Next 3Y3.04%
TALS Yearly Income VS Free CF VS DividendTALS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2019 2020 2021 2022 -20M -40M -60M

More info and screens

TALARIS THERAPEUTICS INC

NASDAQ:TALS (10/19/2023, 8:10:51 PM)

After market: 2.75 +0.03 (+1.1%)

2.72

-0.02 (-0.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2023-08-14/amc
Earnings (Next)11-08 2023-11-08/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners11.37%
Ins Owner Change0%
Market Cap116.44M
Analysts43.33
Price Target20.4 (650%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 55.58%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-51.26%
Min EPS beat(2)-51.26%
Max EPS beat(2)-51.26%
EPS beat(4)2
Avg EPS beat(4)-12.68%
Min EPS beat(4)-51.26%
Max EPS beat(4)11.96%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)60%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-1.79
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-1.4
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0
BVpS3.47
TBVpS3.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.99%
ROE -50.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.01%
ROA(5y)N/A
ROE(3y)-25.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 95.92%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.41
Quick Ratio 15.41
Altman-Z 4.5
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)299.29%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.65%
EPS Next Y22.08%
EPS Next 2Y18.99%
EPS Next 3Y3.04%
EPS Next 5Y9.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.19%
OCF growth 3YN/A
OCF growth 5YN/A